Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year. 

Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.

Which vaccines will India use for immunizing its 1.35 billion population against COVID-19? Where will the money come from? Will it allow sales of these vaccines in the market? As the world’s largest democracy gets set to roll out its immunization plan, here’s a look at a few pertinent questions.